Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 Nov 2020
Historique:
received: 11 10 2019
revised: 08 07 2020
accepted: 20 07 2020
pubmed: 4 8 2020
medline: 15 5 2021
entrez: 4 8 2020
Statut: ppublish

Résumé

Urotensin II (U-II) has been found to be one of the most potent vasoconstrictor (Ames et al., 1999; Bohm et al., 2002) reported till date. U-II exerts its response via activation of a G-protein coupled receptor, Urotensin II receptor(UT). Binding of U-II to UT leads to an instant increase in the inositol phosphate turnover and intracellular Ca

Identifiants

pubmed: 32745605
pii: S0014-2999(20)30483-0
doi: 10.1016/j.ejphar.2020.173391
pii:
doi:

Substances chimiques

Antihypertensive Agents 0
Receptors, G-Protein-Coupled 0
Small Molecule Libraries 0
Urotensins 0
urotensin II receptor, mouse 0
urotensin II 9047-55-6
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173391

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Ruchi Tandon (R)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India. Electronic address: ruchi.tandon@thsti.res.in.

Ajay Soni (A)

Department of Medicinal Chemistry, Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Rakesh K Singh (RK)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Reena Sodhi (R)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Mahesh K Seth (MK)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Sandeep Sinha (S)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Sudhir Sahdev (S)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Ganesh Dhage (G)

Department of Medicinal Chemistry, Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Biswajit Das (B)

Department of Medicinal Chemistry, Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Sunanda G Dastidar (SG)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Raj Kumar Shriumalla (RK)

Department of Pharmacology; Daiichi Sankyo Life Science Research Centre in India, Gurgaon, India.

Kiyoaki Yonesu (K)

End-Organ Disease Laboratories, Daiichi Sankyo Co., Limited., Tokyo, Japan.

Shinji Marumoto (S)

End-Organ Disease Laboratories, Daiichi Sankyo Co., Limited., Tokyo, Japan.

Takahiro Nagayama (T)

Cell Therapy Laboratories, Daiichi Sankyo Co., Limited, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH